In a series of studies, recombinant @entity4020 (rIFN alpha 2a, Roferon-A) was administered alone (273 @entity1 ) or combined with @entity5713 (91 @entity1 ) to @entity1 with @entity791 ( @entity791 )-related @entity2826 ( @entity2826 ). @entity1 were treated with daily doses of rIFN alpha 2a ranging from 3 to 54 million international units (I.U.) administered intramuscularly. A dose of 36 million I.U. daily for approximately 10 weeks followed by a three times weekly maintenance schedule with the same dose resulted in the best overall therapeutic benefit. An escalating-dose regimen of 3, 9, and 18 million I.U. daily, each for 3 days, followed by 36 million I.U. daily, produced equivalent therapeutic benefit with amelioration of acute @entity137 in some @entity1 . Response was more likely in @entity1 without a history of @entity1292 or B symptoms ( @entity221 , night sweats, or @entity353 ). Response rate increased with increasing baseline @entity404 lymphocyte count and was 45.5% in @entity1 with a @entity404 count of greater than 400/mm3. Responding @entity1 with a @entity404 count of greater than 200/mm3 had a distinct survival advantage over @entity1 who had similar @entity404 counts but whose @entity5 did not regress with therapy. The addition of @entity5713 increased @entity137 and did not improve the response rate or prolong survival. Side effects included fatigue, @entity221 , chills, @entity925 , @entity10 , @entity448 , @entity390 , @entity294 , and @entity1296 . Mild abnormalities in hematologic and liver function tests occurred in some @entity1 . Most adverse effects diminished or resolved with continued therapy. We conclude that rIFN alpha 2a offers important therapeutic benefit in a select group of @entity1 with @entity791 -related @entity2826 .

@entity4020 in the treatment of @entity791 -related XXXX .

@entity1 :: ('9606', 'Species') :: ['men', 'Patients', 'patients'] @entity2826 :: ('MESH:D012514', 'Disease') :: ["Kaposi's sarcoma", 'KS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgias'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity4020 :: ('3440', 'Gene') :: ['interferon-alpha 2a'] @entity1292 :: ('MESH:D009894', 'Disease') :: ['opportunistic infection'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches'] @entity791 :: ('MESH:D000163', 'Disease') :: ['acquired immunodeficiency syndrome', 'AIDS'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity2826 :: (MESH:D012514,Disease) :: ['Kaposi's sarcoma']
